Palmitoylethanolamide Effects on Intraocular Pressure After Nd:YAG Laser Iridotomy: An Experimental Clinical Study

Pescosolido, Nicola; Librando, Aloisa; Puzzono, Marta; Nebbioso, Marcella

doi:10.1089/jop.2010.0191

Cited by 14 publications

(14 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pescosolido et al. () administered 600 mg of microPEA (Visimast ® ) per day for 15 days. Subjects acted as their own controls, and no comment was made about possible side effects.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Safety of micronized palmitoylethanolamide (microPEA): lack of toxicity and genotoxic potential

Nestmann¹

2016

Food Science & Nutrition

View full text Add to dashboard Cite

Palmitoylethanolamide (PEA) is a natural fatty acid amide found in a variety of foods, which was initially identified in egg yolk. MicroPEA of defined particle size (0.5–10 μm) was evaluated for mutagenicity in Salmonella typhimurium, for clastogenicity/aneuploidy in cultured human lymphocytes, and for acute and subchronic rodent toxicity in the rat, following standard OECD test protocols, in accordance with Good Laboratory Practice (GLP). PEA did not induce mutations in the bacterial assay using strains TA1535, TA97a, TA98, TA100, and TA102, with or without metabolic activation, in either the plate incorporation or liquid preincubation methods. Similarly, PEA did not induce genotoxic effects in human cells treated for 3 or 24 h without metabolic activation, or for 3 h with metabolic activation. PEA was found to have an LD50 greater than the limit dose of 2000 mg/kg body weight (bw), using the OECD Acute Oral Up and Down Procedure. Doses for the 90‐day rat oral toxicity study were based on results from the preliminary 14‐day study, that is, 250, 500, and 1000 mg/kg bw/day. The No Effect Level (NOEL) in both subchronic studies was the highest dose tested.

show abstract

“…Pescosolido et al. () administered 600 mg of microPEA (Visimast ® ) per day for 15 days. Subjects acted as their own controls, and no comment was made about possible side effects.…”

Section: Discussionmentioning

confidence: 99%

“…One adverse event was reported and considered to be irrelevant to microPEA (Normast ® 300) exposure of 300 mg, twice a day; 26 subjects completed the study. Pescosolido et al (2011) administered 600 mg of microPEA (Visimast ® ) per day for 15 days. Subjects acted as their own controls, and no comment was made about possible side effects.…”

mentioning

confidence: 99%

Safety of micronized palmitoylethanolamide (microPEA): lack of toxicity and genotoxic potential

Nestmann¹

2016

Food Science & Nutrition

View full text Add to dashboard Cite

show abstract

“…Palmitoylethanolamide (PEA) might be a retinoprotectant, as it has cytoprotective and immune (and glia-) modulating properties and is characterized by multiple tissue-targets (mast cells, glia cells, and retina cells) [ 8 ]. PEA lowers intraocular pressure, both in normal and in high-pressure glaucoma, as well as after laser iridotomy [ 9 – 12 ]. In an uveitis model, PEA inhibits inflammation and protects eye tissue [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic Retinopathy

Hesselink

Costagliola

Fakhry

et al. 2015

Journal of Ophthalmology

View full text Add to dashboard Cite

Retinopathy is a threat to the eyesight, and glaucoma and diabetes are the main causes for the damage of retinal cells. Recent insights pointed out a common pathogenetic pathway for both disorders, based on chronic inflammation. Palmitoylethanolamide (PEA) is an endogenous cell protective lipid. Since its discovery in 1957 as a biologically active component in foods and in many living organisms, around 500 scientific papers have been published on PEA's anti-inflammatory and neuron-protective properties. PEA has been evaluated for glaucoma, diabetic retinopathy, and uveitis, pathological states based on chronic inflammation, respiratory disorders, and various pain syndromes in a number of clinical trials since the 70s of 20th century. PEA is available as a food supplement (PeaPure) and as diet food for medical purposes in Italy (Normast, PeaVera, and Visimast). These products are notified in Italy for the nutritional support in glaucoma and neuroinflammation. PEA has been tested in at least 9 double blind placebo controlled studies, among which two studies were in glaucoma, and found to be safe and effective up to 1.8 g/day, with excellent tolerability. PEA therefore holds a promise in the treatment of a number of retinopathies. We discuss PEA as a putative anti-inflammatory and retinoprotectant compound in the treatment of retinopathies, especially related to glaucoma and diabetes.

show abstract

“…16 Recently, a clinical study has demonstrated that PEA was effective in reducing the increased IOP after the iridotomy procedure. 17 In another clinical trial, PEA was found to significantly reduce IOP in patients diagnosed with primary open-angle glaucoma (POAG) or with ocular hypertension. 18 For the current study, the first hypothesis to be tested is that PEA may affect aqueous humor outflow.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, clinical trial studies have shown that the PEA can lower increased IOP in eyes that underwent the laser iridotomy procedure 17 and in glaucomatous eyes. 18 In the present study, we have demonstrated that administration of PEA leads to an increased aqueous humor outflow in perfused porcine anterior segments.…”

Section: Discussionmentioning

confidence: 99%

Effects of Palmitoylethanolamide on Aqueous Humor Outflow

Kumar

Qiao

Kumar

et al. 2012

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

Palmitoylethanolamide Effects on Intraocular Pressure After Nd:YAG Laser Iridotomy: An Experimental Clinical Study

Abstract: PEA can counteract the increase of IOP that occurs after iridotomy. It is likely that PEA controls the inflammatory process after iridotomy.

Cited by 14 publications

References 44 publications

Safety of micronized palmitoylethanolamide (microPEA): lack of toxicity and genotoxic potential

Safety of micronized palmitoylethanolamide (microPEA): lack of toxicity and genotoxic potential

Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic Retinopathy

Effects of Palmitoylethanolamide on Aqueous Humor Outflow

Contact Info

Product

Resources

About